These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 34061126)

  • 21. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
    Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
    Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential.
    Kosmas CE; Muñoz Estrella A; Skavdis A; Peña Genao E; Martinez I; Guzman E
    Ther Clin Risk Manag; 2020; 16():1031-1037. PubMed ID: 33149595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.
    Banerjee Y; Pantea Stoian A; Cicero AFG; Fogacci F; Nikolic D; Sachinidis A; Rizvi AA; Janez A; Rizzo M
    Expert Opin Drug Saf; 2022 Jan; 21(1):9-20. PubMed ID: 34596005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inclisiran-New hope in the management of lipid disorders?
    Dyrbuś K; Gąsior M; Penson P; Ray KK; Banach M
    J Clin Lipidol; 2020; 14(1):16-27. PubMed ID: 31879073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?
    Doggrell SA
    Expert Opin Pharmacother; 2020 Nov; 21(16):1971-1974. PubMed ID: 32749892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
    Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translational Population-Pharmacodynamic Modeling of a Novel Long-Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia.
    Gosselin NH; Schuck VJA; Barriere O; Kulmatycki K; Margolskee A; Smith P; He Y
    Clin Pharmacol Ther; 2023 Feb; 113(2):328-338. PubMed ID: 36281788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9.
    German CA; Shapiro MD
    BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
    Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
    Khan SA; Naz A; Qamar Masood M; Shah R
    Am J Cardiol; 2020 Nov; 134():69-73. PubMed ID: 32892993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
    Mahmood T; Shapiro MD
    Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.